Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Impact on behavioral changes due to chronic use of sertraline in Wistar albino rats.

Mukherjee S, Sen S, Biswas A, Barman TK, Tripathi SK.

Indian J Pharmacol. 2015 Nov-Dec;47(6):657-62. doi: 10.4103/0253-7613.169590.

2.

Efficacy and safety of generic escitalopram (Lexacure(®)) in patients with major depressive disorder: a 6-week multicenter, randomized, rater-blinded, escitalopram-comparative, non-inferiority study.

Jeong JH, Bahk WM, Woo YS, Lee KU, Kim do H, Kim MD, Kim W, Yang JC, Lee KH.

Neuropsychiatr Dis Treat. 2015 Oct 9;11:2557-64. doi: 10.2147/NDT.S90796. eCollection 2015.

3.

Symptom severity of bipolar disorder during the menopausal transition.

Marsh WK, Gershenson B, Rothschild AJ.

Int J Bipolar Disord. 2015 Dec;3(1):35. doi: 10.1186/s40345-015-0035-z. Epub 2015 Aug 22.

4.

Presynaptic plasticity as a hallmark of rat stress susceptibility and antidepressant response.

Nieto-Gonzalez JL, Holm MM, Vardya I, Christensen T, Wiborg O, Jensen K.

PLoS One. 2015 Mar 5;10(3):e0119993. doi: 10.1371/journal.pone.0119993. eCollection 2015.

5.

The interaction of escitalopram and R-citalopram at the human serotonin transporter investigated in the mouse.

Jacobsen JP, Plenge P, Sachs BD, Pehrson AL, Cajina M, Du Y, Roberts W, Rudder ML, Dalvi P, Robinson TJ, O'Neill SP, Khoo KS, Morillo CS, Zhang X, Caron MG.

Psychopharmacology (Berl). 2014 Dec;231(23):4527-40. doi: 10.1007/s00213-014-3595-1. Epub 2014 May 9.

6.

Evidence-based, pharmacological treatment guideline for depression in Korea, revised edition.

Won E, Park SC, Han KM, Sung SH, Lee HY, Paik JW, Jeon HJ, Lee MS, Shim SH, Ko YH, Lee KJ, Han C, Ham BJ, Choi J, Hwang TY, Oh KS, Hahn SW, Park YC, Lee MS, Clinical Research Center for Depression.

J Korean Med Sci. 2014 Apr;29(4):468-84. doi: 10.3346/jkms.2014.29.4.468. Epub 2014 Apr 1.

7.

A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?

Sanchez C, Reines EH, Montgomery SA.

Int Clin Psychopharmacol. 2014 Jul;29(4):185-96. doi: 10.1097/YIC.0000000000000023. Review.

9.

P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodents.

O'Brien FE, O'Connor RM, Clarke G, Dinan TG, Griffin BT, Cryan JF.

Neuropsychopharmacology. 2013 Oct;38(11):2209-19. doi: 10.1038/npp.2013.120. Epub 2013 May 14.

10.

Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial.

Dunlop BW, Binder EB, Cubells JF, Goodman MM, Kelley ME, Kinkead B, Kutner M, Nemeroff CB, Newport DJ, Owens MJ, Pace TW, Ritchie JC, Rivera VA, Westen D, Craighead WE, Mayberg HS.

Trials. 2012 Jul 9;13:106. doi: 10.1186/1745-6215-13-106.

11.

Identification of a novel selective serotonin reuptake inhibitor by coupling monoamine transporter-based virtual screening and rational molecular hybridization.

Nolan TL, Lapinsky DJ, Talbot JN, Indarte M, Liu Y, Manepalli S, Geffert LM, Amos ME, Taylor PN, Madura JD, Surratt CK.

ACS Chem Neurosci. 2011 Jun 8;2(9):544-552.

12.

Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label study.

Thase ME, Ninan PT, Musgnung JJ, Trivedi MH.

Prim Care Companion CNS Disord. 2011;13(1). pii: PCC.10m00979. doi: 10.4088/PCC.10m00979blu.

13.

Comparative efficacy of escitalopram in the treatment of major depressive disorder.

Ali MK, Lam RW.

Neuropsychiatr Dis Treat. 2011;7:39-49. doi: 10.2147/NDT.S12531. Epub 2011 Feb 1.

15.

Escitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression.

Leonard B, Taylor D.

J Psychopharmacol. 2010 Aug;24(8):1143-52. doi: 10.1177/0269881109349835. Epub 2010 Feb 10. Review.

16.

Triple reuptake inhibitors: a premise and promise.

Marks DM, Pae CU, Patkar AA.

Psychiatry Investig. 2008 Sep;5(3):142-7. doi: 10.4306/pi.2008.5.3.142. Epub 2008 Sep 30.

17.

Serotonin transporter gene polymorphism and treatment response to serotonin reuptake inhibitor (escitalopram) in depression: An open pilot study.

Margoob MA, Mushtaq D, Murtza I, Mushtaq H, Ali A.

Indian J Psychiatry. 2008 Jan;50(1):47-50. doi: 10.4103/0019-5545.39759.

18.

Continuing medical education.

Andrade C.

Indian J Psychiatry. 2008 Jul;50(3):209-12. doi: 10.4103/0019-5545.43631. No abstract available.

19.

Triple reuptake inhibitors: the next generation of antidepressants.

Marks DM, Pae CU, Patkar AA.

Curr Neuropharmacol. 2008 Dec;6(4):338-43. doi: 10.2174/157015908787386078.

20.

Desvenlafaxine in the treatment of major depressive disorder.

Lourenco MT, Kennedy SH.

Neuropsychiatr Dis Treat. 2009;5:127-36. Epub 2009 Apr 8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk